药物所致弥漫性肺疾病:基于法国药物警戒数据库37年全国观察性研究
96.7%的病例为严重不良事件,13.3%导致死亡。最常见的表现为间质性肺病(51.0%)、肺水肿(15.6%)和肺纤维化(10.5%);抗肿瘤药(31.2%)和心血管药(29.1%)是最主要的治疗类别,胺碘酮(10.0%)和甲氨蝶呤(3.1%)为最常见可疑药物。
要点
- 药物所致弥漫性肺疾病多为严重不良事件,死亡率达13.3%。
- 抗肿瘤药和心血管药是最常见涉及的治疗类别。
- 胺碘酮和甲氨蝶呤是报告最多的可疑药物。
核心结论
- 药物所致弥漫性肺疾病严重且可能致命,准确诊断并及时停用可疑药物至关重要。
研究设计与样本
- 回顾性研究,纳入法国药物警戒数据库1985年1月1日至2022年4月1日登记的成年患者病例,共分析7234例。
主要发现
- 96.7%的病例为严重不良事件,13.3%导致死亡。
- 男性占54.4%,中位年龄69岁(范围18-103岁)。
- 最常见不良事件为间质性肺病(51.0%)、肺水肿(15.6%)和肺纤维化(10.5%)。
- 抗肿瘤药(31.2%)和心血管药(29.1%)是最主要的治疗类别。
- 最常见可疑药物为胺碘酮(10.0%)和甲氨蝶呤(3.1%)。
临床怎么用
- 临床应警惕药物所致弥漫性肺疾病,及时识别并停用可疑药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-induced interstitial lung disease (DI-ILD) is a heterogeneous subgroup of interstitial lung disease (ILD). The number of molecules involved is increasing with time. Due to their low incidence, DI-ILDs may be detected only after a drug has been marketed, notably through adverse drug reaction (ADR) reports to pharmacovigilance centres. The aim of our study was to describe drug-induced diffuse lung disease cases notified to and recorded by the French Pharmacovigilance Database (FPVD), reported clinical pictures and the potentially causal drugs. METHODS: This retrospective study included cases registered in the FPVD from 1 January 1985 to 1 April 2022 which had ADRs coded in MedDRA with a High-Level Group Term "Lower respiratory tract disorders (excluding obstruction and infection)" involving patients aged ≥18 years. RESULTS: We analysed 7234 cases involving 13 059 suspect medications and 1112 specific molecules. Cases were categorised as serious in 96.7% and death ensued in 13.3%. Males accounted for 54.4% of the cases. Median (range) age was 69 (18-103) years. The most prevalent ADRs were "Interstitial lung disease" (51.0%), "Pulmonary oedema" (acute/non-acute) (15.6%) and "Pulmonary fibrosis" (10.5%). Anti-cancer drugs (31.2%) and cardiovascular drugs (29.1%) were the most prominent therapeutic classes involved, with amiodarone being the most commonly reported suspected drug (10.0%), followed by methotrexate (3.1%). CONCLUSION: This study from a large nationwide dataset spanning 37 years is the largest known to date. Drug-induced diffuse lung diseases are serious with a potentially fatal outcome. Accurate diagnoses remain essential to identify the diseases properly and discontinue the culprit drug urgently.
引用
- Yavordios S, Beltramo G, Freppel R, et al. Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French Pharmacovigilance Database. Eur Respir J. 2025. PMID: 39510554. doi:10.1183/13993003.00756-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。